Cuba´s Center for State Control of medicines, Equipment and Medical Devices (CECMED) on Wednesday authorized the start of a phase-II clinical trial with the vaccine candidate CIGB2020, seeking to stimulate the immune response against acute respiratory infections.
After several months of hard work for scientists at the Center for Genetic Engineering and Biotechnology (CIGB), Abdala proved to be a safe anti-COVID-19 vaccine candidate, immunogenic and with an efficacy of 92.28% in the prevention of the symptomatic disease.
Cuba will immunize its entire population against COVID-19 during this year 2021, based on the proven efficacy of its vaccine candidates Soberana 02 and Abdala, the first in phase III of a clinical trial and the second to begin in the coming days.
Cuba has registered four vaccine candidates against COVID-19 that are currently on clinical trials, after Mambisa and Abdala, developed by the Genetic Engineering and Biotechnology Center (CIGB), were authorized for this phase of the study.
Cuban Deputy Prime Minister Roberto Morales Ojeda visited on Monday 21, the Finlay Vaccine Institute of Havana to monitor the progress of the ongoing projects in the center, especially the country’s vaccine against Covid-19, Soberana 01.